Katie McKenna will discuss how oncolytic viral therapy enhances CAR-T cell killing of cancer cells.

Researchers devise strategies to improve checkpoint inhibitor therapy and predict patient response.

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

Surveillance Gaps: How Cancer Arises

A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.

Jeffrey Weidner and Eric Niederkofler will discuss strategies for optimizing dose response assays.

LuZhe Sun will discuss TGFβ signaling during cancer progression and how researchers can target this pathway.

Arnold Levine will discuss his discovery of p53 and the evolution of the field since then, and Jon Chen will discuss the use of single-cell phosphoproteomics in identifying changes in key signaling networks, including p53.

A look at the molecular processes that may feed into the tumor-fighting effects of physical activity

Gene editing can knock out genes crucial to cervical tumor cells’ survival, researchers report.

Studies point to a role for physical activity in fighting malignancies, improving treatment outcomes, and fostering overall health in patients.

Researchers use a new way to deliver CRISPR/Cas9 to tumors in mice, wiping out the cancer.

Researchers use 3-D printing technology to construct a brain cancer model that accurately recapitulated in vivo biology and predicted patient drug responses.

How researchers create a glioblastoma on a chip that can predict patients’ response to treatments

Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions.

Researchers plan to turn cancer cells into defectors, engineering them to kill the tumors from whence they came, and have tested the approach in mice.

More than one-fifth of individuals treated with the genetically modified virus survived at least three years.

The immunotherapy eliminated a woman’s metastatic lesions and kept her disease-free for two years.

Lonza will employ more than 200 full-time staff to work at the Texas-based facility, the company says.